On 20 January 2025 the General Office of the Ministry of Industry and Information Technology and the Department of General Affairs of the National Medical Products Administration issued a joint notice launching the 2025 AI medical device innovation challenge. It is a joint deployment by the two departments in AI healthcare, aimed squarely at product research and industrialisation.
The three task categories
The challenge covers three categories: intelligent decision-support products, brain-computer hybrid intelligence products, and supporting environments. Placing “products” and “supporting conditions” side by side shows that policy attention is on more than individual products; it also covers the infrastructure that lets products land and be validated.
For companies in AI healthcare, the challenge matters because it offers a predictable channel: task-driven work links research direction with regulatory recognition, reducing uncertainty at the approval and clinical validation stage. See our notes on the NMPA opinion on AI drug regulation and on the AI Plus healthcare implementation opinion.
The special compliance structure of healthcare AI
AI products in healthcare have a distinctive compliance structure: they must satisfy medical device registration and quality requirements and also handle medical data and personal information lawfully. The two sets of requirements belong to different regulatory systems, and companies often prepare thoroughly on one side and thinly on the other.
A mechanism like the challenge effectively puts technical work and regulatory dialogue on the same timeline, helping companies surface compliance issues early. See our notes on the ML medical device innovation guidance and on the FDA and EMA good AI practice principles.
A direction worth watching
The task design shows growing policy attention to the “supporting environment”, including data, testing and validation conditions. This aligns with international trends in healthcare AI governance: algorithm performance alone is no longer enough to support deployment, and a verifiable, traceable support system is increasingly decisive.
For companies in this space, joining such tasks early can help secure influence while standards and regulatory expectations are still forming.
This article is based on the joint notice of the MIIT General Office and the NMPA Department of General Affairs and public information and is for reference only; it does not constitute legal advice.